|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOMO2 |
Gene summary for NOMO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOMO2 | Gene ID | 283820 |
| Gene name | NODAL modulator 2 | |
| Gene Alias | Nomo | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5JPE7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 283820 | NOMO2 | P4T-E | Human | Esophagus | ESCC | 6.27e-06 | 1.70e-01 | 0.1323 |
| 283820 | NOMO2 | P8T-E | Human | Esophagus | ESCC | 5.00e-17 | 3.15e-01 | 0.0889 |
| 283820 | NOMO2 | P10T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.20e-01 | 0.116 |
| 283820 | NOMO2 | P11T-E | Human | Esophagus | ESCC | 2.06e-07 | 2.66e-01 | 0.1426 |
| 283820 | NOMO2 | P12T-E | Human | Esophagus | ESCC | 2.86e-20 | 3.76e-01 | 0.1122 |
| 283820 | NOMO2 | P15T-E | Human | Esophagus | ESCC | 6.21e-15 | 3.00e-01 | 0.1149 |
| 283820 | NOMO2 | P16T-E | Human | Esophagus | ESCC | 8.73e-28 | 5.07e-01 | 0.1153 |
| 283820 | NOMO2 | P17T-E | Human | Esophagus | ESCC | 4.48e-07 | 3.15e-01 | 0.1278 |
| 283820 | NOMO2 | P19T-E | Human | Esophagus | ESCC | 4.64e-06 | 4.05e-01 | 0.1662 |
| 283820 | NOMO2 | P20T-E | Human | Esophagus | ESCC | 3.75e-11 | 2.91e-01 | 0.1124 |
| 283820 | NOMO2 | P21T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.41e-01 | 0.1617 |
| 283820 | NOMO2 | P22T-E | Human | Esophagus | ESCC | 9.02e-11 | 1.98e-01 | 0.1236 |
| 283820 | NOMO2 | P23T-E | Human | Esophagus | ESCC | 7.50e-13 | 2.97e-01 | 0.108 |
| 283820 | NOMO2 | P24T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.63e-01 | 0.1287 |
| 283820 | NOMO2 | P26T-E | Human | Esophagus | ESCC | 1.85e-18 | 3.14e-01 | 0.1276 |
| 283820 | NOMO2 | P27T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.38e-01 | 0.1055 |
| 283820 | NOMO2 | P28T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.01e-01 | 0.1149 |
| 283820 | NOMO2 | P30T-E | Human | Esophagus | ESCC | 2.89e-13 | 3.43e-01 | 0.137 |
| 283820 | NOMO2 | P32T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.73e-01 | 0.1666 |
| 283820 | NOMO2 | P36T-E | Human | Esophagus | ESCC | 9.55e-10 | 3.02e-01 | 0.1187 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOMO2 | SNV | Missense_Mutation | novel | c.1738N>A | p.Val580Met | p.V580M | Q5JPE7 | protein_coding | deleterious(0.01) | benign(0.306) | TCGA-A2-A0ST-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NOMO2 | SNV | Missense_Mutation | novel | c.1131N>G | p.Ile377Met | p.I377M | Q5JPE7 | protein_coding | tolerated(0.06) | possibly_damaging(0.622) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NOMO2 | SNV | Missense_Mutation | novel | c.839N>T | p.Ser280Phe | p.S280F | Q5JPE7 | protein_coding | tolerated(0.05) | benign(0.359) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NOMO2 | SNV | Missense_Mutation | novel | c.162N>G | p.Ile54Met | p.I54M | Q5JPE7 | protein_coding | deleterious(0) | benign(0.378) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| NOMO2 | SNV | Missense_Mutation | c.1258N>A | p.Pro420Thr | p.P420T | Q5JPE7 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
| NOMO2 | SNV | Missense_Mutation | rs758517656 | c.2065N>A | p.Asp689Asn | p.D689N | Q5JPE7 | protein_coding | tolerated(0.15) | benign(0.223) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| NOMO2 | SNV | Missense_Mutation | rs554396078 | c.967G>A | p.Val323Met | p.V323M | Q5JPE7 | protein_coding | tolerated(0.1) | benign(0.226) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| NOMO2 | SNV | Missense_Mutation | rs141824052 | c.2240N>A | p.Gly747Asp | p.G747D | Q5JPE7 | protein_coding | tolerated(0.09) | possibly_damaging(0.573) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOMO2 | SNV | Missense_Mutation | novel | c.1741N>C | p.Ser581Pro | p.S581P | Q5JPE7 | protein_coding | tolerated(0.21) | benign(0.184) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| NOMO2 | SNV | Missense_Mutation | novel | c.1817N>G | p.Gln606Arg | p.Q606R | Q5JPE7 | protein_coding | tolerated(0.17) | benign(0.439) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |